These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8370634)

  • 1. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I; Adak B; Budancamanak M; Demirel A; Ediz L
    Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.
    Gennari C; Agnusdei D; Camporeale A
    Osteoporos Int; 1993; 3 Suppl 1():208-10. PubMed ID: 8461563
    [No Abstract]   [Full Text] [Related]  

  • 7. Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty.
    Peichl P; Marteau R; Griesmacher A; Kumpan W; Schedl R; Prosquil E; Fasol P; Bröll H
    J Bone Miner Metab; 2005; 23(3):243-52. PubMed ID: 15838628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R; Gonnelli S; Zacchei F; Bigazzi S; Vattimo A; Avioli LV; Gennari C
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
    Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
    Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
    Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
    Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
    Overgaard K; Lindsay R; Christiansen C
    Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
    Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
    Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
    Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
    J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
    Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
    Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW; Yeung SS
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
    Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
    Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.